nach oben

Erschienen in:

09.08.2017 | Original Article

Vertebral fractures assessed with dual-energy X-ray absorptiometry in patients with Addison’s disease on glucocorticoid and mineralocorticoid replacement therapy

verfasst von: Valentina Camozzi, Corrado Betterle, Anna Chiara Frigo, Veronica Zaccariotto, Martina Zaninotto, Erica De Caneva, Paola Lucato, Walter Gomiero, Silvia Garelli, Chiara Sabbadin, Monica Salvà, Miriam Dalla Costa, Marco Boscaro, Giovanni Luisetto

Erschienen in: Endocrine | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

to assess bone damage and metabolic abnormalities in patients with Addison’s disease given replacement doses of glucocorticoids and mineralocorticoids.

Methods

A total of 87 patients and 81 age-matched and sex-matched healthy controls were studied. The following parameters were measured: urinary cortisol, serum calcium, phosphorus, creatinine, 24-h urinary calcium excretion, bone alkaline phosphatase, parathyroid hormone, serum CrossLaps, 25 hydroxyvitamin D, and 1,25 dihydroxyvitamin D. Clear vertebral images were obtained with dual-energy X-ray absorptiometry in 61 Addison’s disease patients and 47 controls and assessed using Genant’s classification.

Results

Nineteen Addison’s disease patients (31.1%) had at least one morphometric vertebral fracture, as opposed to six controls (12.8%, odds ratio 3.09, 95% confidence interval 1.12–8.52). There were no significant differences in bone mineral density parameters at any site between patients and controls. In Addison’s disease patients, there was a positive correlation between urinary cortisol and urinary calcium excretion. Patients with fractures had a longer history of disease than those without fractures. Patients taking fludrocortisone had a higher bone mineral density than untreated patients at all sites except the lumbar spine.

Conclusions

Addison’s disease patients have more fragile bones irrespective of any decrease in bone mineral density. Supra-physiological doses of glucocorticoids and longer-standing disease (with a consequently higher glucocorticoid intake) might be the main causes behind patients’ increased bone fragility. Associated mineralocorticoid treatment seems to have a protective effect on bone mineral density.

W. Arlt, B. Allolio, Adrenal insufficiency. Lancet 361, 1881–1893 (2003)CrossRefPubMed

C. Betterle, L. Morlin, Autoimmune Addison’s disease. Endocrine. Development 20, 161–172 (2011)

M. Quinkler, F. Beuschlein, S. Hahner, G. Meyer, C. Schöfl, G.K. Stalla, Adrenal cortical insufficiency - a life threatening illness with multiple etiologies. Dtsch. Arztebl. Int. 110, 882–888 (2013)PubMedPubMedCentral

M.M. Erichsen, K. Lovas, B. Skinningsrud, A.B. Wolff, D.E. Undlien, J. Svartberg, K.J. Fougner, T.J. Berg, J. Bollerslev, B. Mella, J.A. Carlson, H. Erlich, E.S. Husebye, Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. J. Clin. Endocr. Metab. 94, 4882–4890 (2009)CrossRefPubMed

C. Betterle, R. Scarpa, S. Garelli, L. Morlin, F. Lazzarotto, F. Presotto, G. Coco, S. Masiero, A. Parolo, M.P. Albergoni, R. Favero, S. Barollo, M. Salvà, D. Basso, S. Chen, B. Rees Smith, J. Furmaniak, F. Mantero, Addison’s disease: a survey on 633 patients in Padova. Eur. J. Endocrinol. 169, 773–784 (2013)CrossRefPubMed

C. Betterle, C. Dal Pra, F. Mantero, R. Zanchetta, Autoimmune adrenal insufficiency and autoimmune polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr. Rev. 23, 327–364 (2002)CrossRefPubMed

G.S. Eisenbarth, P.A. Gottlieb, Autoimmune polyendocrine syndromes. New Engl. J. Med. 13, 2068–2079 (2004)CrossRef

A. Soderbergh, O. Winqvist, I. Norheim, F. Rorsman, E.S. Husebye, O. Dolva, F.A. Karlsson, O. Kämpe, Adrenal autoantibodies and organ-specific autoimmunity in patients with Addison’s disease. Clin. Endocrinol. 45, 453–460 (1996)CrossRef

M. Fichna, P. Fichna, M. Gryczynska, J. Walkowiak, M. Zurawek, J. Sowinski, Screening for associated autoimmune disorders in Polish patients with Addison’s disease. Endocrine 37, 349–360 (2010)CrossRefPubMed

10.

A. Soderbergh, A.G. Myhre, O. Ekwall, G. Gebre-Medhin, H. Hedstrand, E. Landgren, A. Miettinen, P. Eskelin, M. Halonen, T. Tuomi, J. Gustafsson, E.S. Husebye, J. Perheentupa, M. Gylling, M.P. Manns, F. Rorsman, O. Kämpe, T. Nilsson, Prevalence and clinical associations of 10 defined autoantibodies in autoimmune polyendocrine syndrome type I. J. Clin. Endocr. Metab. 89, 557–562 (2004)CrossRefPubMed

11.

E.S. Husebye, J. Perheentupa, R. Rautemaa, O. Kämpe, Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I. J. Intern. Med 265, 514–529 (2009)CrossRefPubMed

12.

Ø. Bruserud, B.E. Oftedal, A.B. Wolff, E.S. Husebye, AIRE-mutations and autoimmune disease. Curr. Opin. Immunol. 6, 8–15 (2016)CrossRef

13.

E.S. Husebye, B. Allolio, W. Arlt, K. Badenhoop, S. Bensing, C. Betterle, A. Falorni, E.H. Gan, A.L. Hulting, A. Kasperlik-Zaluska, O. Kämpe, K. Løvås, G. Meyer, S.H. Pearce, Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency. J. Intern. Med. 275, 104–115 (2014)CrossRefPubMed

14.

A. Grossman, G. Johannsson, M. Quinkler, P. Zelissen, Therapy of endocrine disease. Perspectives on the management of adrenal insufficiency: clinical insights from across Europe. Eur. J. Endocrinol. 21, R165–R175 (2013)CrossRef

15.

A. Falorni, V. Minarelli, S. Morelli, Therapy of adrenal insufficiency: an update. Endocrine 43, 514–528 (2013)CrossRefPubMed

16.

G. Johannsson, iA. Falorn, S. Skrtic, H. Lennernäs, M. Quinkler, J.P. Monson, P.M. Stewart, Adrenal insufficiency: review of clinical outcomes with current GC replacement therapy. Clin. Endocrinol. (Oxf.) 82, 2–11 (2015)CrossRef

17.

J.P. Devogelaer, J. Crabbé; Nagant de Deuxchaisnes, C, Bone mineral density in Addison’s disease: evidence for an effect of adrenal androgens on bone mass. Brit. Med. J. (Clin. Res Ed.) 294, 798–800 (1987)CrossRef

18.

P.M. Zelissen, R.J. Croughs, P.P. van Rijk, J.A. Raymakers, Effect of MC replacement therapy on bone mineral density in patients with Addison disease. Ann. Intern. Med. 120, 207–210 (1994)CrossRefPubMed

19.

M.A. Valero, M. Leon, M.P. Ruiz Valdepeñas, L. Larrodera, M.B. Lopez, K. Papapietro, A. Jara, F. Hawkins, Bone density and turnover in Addison’s disease: effect of glucocorticoid treatment. Bone Miner. 26, 9–17 (1994)CrossRefPubMed

20.

F. Heureux, D. Maiter, Y. Boutsen, J.P. Devogelaer, J. Jamart, J. Donckier, Evaluation of corticosteroid replacement therapy and its effect on bones in Addison’s disease. Ann. Endocrinol. (Paris) 61, 179–183 (2000)

21.

E. Jódar, M.P. Valdepeñas, G. Martinez, A. Jara, F. Hawkins, Long-term follow-up of bone mineral density in Addison’s disease. Clin. Endocrinol. (Oxf.) 58, 617–620 (2003)CrossRef

22.

K.R. Koetz, M. Ventz, S. Diederich, M. Quinkler, Bone mineral density is not significantly reduced in adult patients on low-dose glucocorticoid replacement therapy. J. Clin. Endocr. Metab. 97, 85–92 (2012)CrossRefPubMed

23.

D.D. Chandy, E. Bhatia, Bone mineral density in patients with Addison disease on replacement therapy with prednisolone. Endocr. Pract. 22, 434–439 (2016)CrossRefPubMed

24.

G. Mazziotti, T. Porcelli, A. Bianchi, V. Cimino, I. Patelli, C. Mejia, A. Fusco, A. Giampietro, L. De Marinis, A. Giustina, Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency. Eur. J. Endocrinol. 163, 15–20 (2010)CrossRefPubMed

25.

R.D. Mosteller, Simplified calculation of body surface area. N. Engl. J. Med. 317, 1098 (1987)PubMed

26.

H.K. Genant, M. Jergas, L. Palermo, M. Nevitt, R.S. Valentin, D. Black, S.R. Cummings, Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. The study of osteoporotic fractures research group. J. Bone Miner. Res. 11, 984–996 (1996)CrossRefPubMed

27.

N. Binkley, D. Krueger, R. Gangnon, H.K. Genant, M.K. Drezner, Lateral vertebral assessment: a valuable technique to detect clinically significant vertebral fractures. Osteoporos. Int. 16, 1513–8 (2005)CrossRefPubMed

28.

I.C. Hospers, J.G. van der Laan, C.J. Zeebregts, P. Nieboer, B.H. Wolffenbuttel, R.A. Dierckx, H.G. Kreeftenberg, P.L. Jager, R.H. Slart, Vertebral fracture assessment in supine position: comparison by using conventional semiquantitative radiography and visual radiography. Radiology 251, 822–828 (2009)CrossRefPubMed

29.

T. Fuerst, C. Wu, H.K. Genant, G. von Ingersleben, Y. Chen, C. Johnston, M.J. Econs, N. Binkley, T.J. Vokes, G. Crans, B.H. Mitlak, Evaluation of vertebral fracture assessment by dual X-ray absorptiometry in a multicenter setting. Osteoporos. Int. 20, 1199–1205 (2009)CrossRefPubMed

30.

P.L. Jager, S. Jonkman, W. Koolhaas, A. Stiekema, B.H. Wolffenbuttel, R.H. Slart, Combined vertebral fracture assessment and bone mineral density measurement: a new standard in the diagnosis of osteoporosis in academic populations. Osteoporos. Int. 22, 1059–1068 (2011)CrossRefPubMed

31.

K. Løvås, C.G. Gjesdal, M. Christensen, A.B. Wolff, B. Almås, J. Svartberg, K.J. Fougner, U. Syversen, J. Bollerslev, J.A. Falch, P.J. Hunt, V.K. Chatterjee, E.S. Husebye, Glucocorticoid replacement therapy and pharmacogenetics in Addison’s disease: effects on bone. Eur. J. Endocrinol. 160, 993–1002 (2009)CrossRefPubMed

32.

S. Björnsdottir, M. Sääf, S. Bensing, O. Kämpe, K. Michaëlsson, J.F. Ludvigsson, Risk of hip fracture in Addison’s disease: a population-based cohort study. J. Intern. Med 270, 187–195 (2011)CrossRefPubMed

33.

F. Heureux, D. Maiter, Y. Boutsen, J.P. Devogelaer, Jamar,t J., Donckier J.: evaluation of corticosteroid replacement therapy and its effect on bones in Addison’s disease. Ann. Endocrinol. (Paris) 61, 179–183 (2000)

34.

E. Jódar, M.P. Valdepeñas, G. Martinez, A. Jara, F. Hawkins, Long-term follow-up of bone mineral density in Addison’s disease. Clin. Endocrinol. (Oxf.) 58, 617–620 (2003)CrossRef

35.

G.D. Braatvedt, M. Joyce, M. Evans, J. Clearwater, I.R. Reid, Bone mineral density in patients with treated Addison’s disease. Osteoporos. Int 10, 435–440 (1999)CrossRefPubMed

36.

C.M. Florkowski, S.J. Holmes, J.R. Elliot, R.A. Donald, E.A. Espiner, Bone mineral density is reduced in female but not male subjects with Addison’s disease. N. Z. Med. J. 107, 52–53 (1994)PubMed

37.

D.D. Chandy, E. Bhatia, Bone mineral density in patients with Addison’s disease on replacement therapy with prednisolone. Endocr. Pract. 22, 434–439 (2016)CrossRefPubMed

38.

P.M. Zelissen, R.J. Croughs, P.P. van Rijk, J.A. Raymakers, Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Ann. Intern. Med. 120, 207–210 (1994)CrossRefPubMed

39.

N. Chikada, T. Imaki, M. Hotta, K. Sato, K. Takano, An assessment of bone mineral density in patients with Addison’s disease and isolated ACTH deficiency treated with glucocorticoid. Endocr. J. 51, 355–360 (2004)CrossRefPubMed

40.

41.

L.A. Behan, G. Kelleher, M.J. Hannon, J.J. Brady, B. Rogers, W. Tormey, D. Smith, C.J. Thompson, M.J. McKenna, A. Agha, Low-dose hydrocortisone replacement therapy is associated with improved bone remodelling balance in hypopituitary male patients. Eur. J. Endocrinol. 170, 141–150 (2013)CrossRefPubMed

42.

J. Schulz, K.R. Frey, M.S. Cooper, K. Zopf, M. Ventz, S. Diederich, M. Quinkler, Reduction in daily hydrocortisone dose improves bone health in primary adrenal insufficiency. Eur. J. Endocrinol. 174, 531–538 (2016)CrossRefPubMed

43.

G. Mazziotti, A. Angeli, J.P. Bilezikian, E. Canalis, A. Giustina, Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol. Metab. 7, 144–149 (2006)CrossRef

44.

F.P. Cappuccio, N.D. Markandu, G.A. MacGregor, Renal handling of calcium and phosphate during mineralocorticoid administration in normal subjects. Nephron 48, 280–283 (1988)CrossRefPubMed

45.

W.N. Suki, R.S. Schwettmann, F.C. Rector Jr, D.W. Seldin, Effect of chronic mineralocorticoid administration on calcium excretion in the rat. Am. J. Physiol. 215, 71–74 (1968)PubMed

46.

E. Rossi, C. Sani, F. Perazzoli, M.C. Casoli, A. Negro, C. Dotti, Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas. Am. J. Hypertens. 8, 884–893 (1995)CrossRefPubMed

47.

L. Ceccoli, V. Ronconi, L. Giovannini, M. Marcheggiani, F. Turchi, M. Boscaro, G. Giacchetti, Bone health and aldosterone excess. Osteoporos. Int. 24, 2801–2807 (2013)CrossRefPubMed

48.

L.Petramala, L.Zinnamosca, A.Settevendemmie, C.Marinelli, M.Nardi, A.Concistrè, F.Corpaci, G.Tonnarini, G.De Toma, C.Letizia Bone and Mineral metabolism in patients with primary aldosteronism.Int. J. Endocrinol (2014). doi:10.1155/2014/836529PubMedPubMedCentral

49.

Y. Zhang, B. Feng, Association of serum parathyrine and calcium levels with primary aldosteronism: a meta-analysis. Int. J. Clin. Exp. Med. 8, 14625–14633 (2015)PubMedPubMedCentral

50.

S. Beavan, A. Horner, S. Bord, D. Ireland, J. Compston, Colocalization of glucocorticoid and mineralocorticoid receptors in human bone. J. Bone Miner. Res. 16, 1496–1504 (2001)CrossRefPubMed

51.

N.Z. Lu, J.B. Collins, S.F. Grissom, J.A. Cidlowski, Selective regulation of bone cell apoptosis by translational isoforms of the glucocorticoid receptor. Mol. Cell Biol. 27, 7143–7160 (2007)CrossRefPubMedPubMedCentral

52.

R. La Corte, F. Trotta, S. Adami, Glucocorticoid receptors and bone. Curr. Pharm. Des. 16, 3586–3592 (2010)CrossRefPubMed

53.

C.M. Jewell, A.B. Scoltock, B.L. Hamel, M.R. Yudt, J.A. Cidlowski, Complex human glucocorticoid receptor dim mutations define glucocorticoid-induced apoptotic resistance in bone cells. Mol. Endocrinol. 26, 244–256 (2012)CrossRefPubMed

54.

P. Moutsatsou, E. Kassi, A.G. Papavassiliou, Glucocorticoid receptor signaling in bone cells. Trends Mol. Med. 18, 348–359 (2012)CrossRefPubMed

55.

H.H. Conaway, P. Henning, A. Lie, J. Tuckermann, U.H. Lerner, Activation of dimeric glucocorticoid receptors in osteoclast progenitors potentiates RANKL-induced mature osteoclast bone resorbing activity. Bone 93, 43–54 (2016)CrossRefPubMed

56.

M.K. Agarwal, F. Mirshahi, M. Mirshahi, S. Bracq, J. Chentoufi, M. Hott, A. Jullienne, P.J. Marie, Evidence for receptor-mediated mineralocorticoid action in rat osteoblastic cells. Am. J. Physiol. 270, C1088–C1095 (1996)CrossRefPubMed

57.

T. Fumoto, K.A. Ishii, M. Ito, S. Berger, G. Schütz, K. Ikeda, Mineralocorticoid receptor function in bone metabolism and its role in glucocorticoid-induced osteopenia. Biochem. Biophys. Res. Commun. 447, 407–412 (2014)CrossRefPubMed

58.

K.K. Miller, B.M. Biller, J. Hier, E. Arena, A. Klibanski, Androgens and bone density in women with hypopituitarism. J. Clin. Endocr. Metab. 87, 2770–2776 (2002)CrossRefPubMed

59.

L.J. Dominguez, M. Barbagallo, L. Moro, Collagen overglycosylation: a biochemical feature that may contribute to bone quality. Biochem. Biophys. Res. Commun. 330, 1–4 (2005)CrossRefPubMed

60.

E. Seeman, P.D. Delmas, Bone quality - the material and structural basis of bone strength and fragility. N. Engl. J. Med. 354, 2250–2261 (2006)CrossRefPubMed

61.

E. Canalis, G. Mazziotti, A. Giustina, J.P. Bilezikian, Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos. Int. 18, 1319–1328 (2007)CrossRefPubMed

62.

G. Mazziotti, A. Giustina, Glucocorticoids and the regulation of growth hormone secretion. Nat. Rev. Endocrinol. 9, 265–276 (2013)CrossRefPubMed

63.

O. Svejme, H.G. Ahlborg, J.Å. Nilsson, M.K. Karlsson, Early menopause and risk of osteoporosis, fracture and mortality: a 34-year prospective observational study in 390 women. Br. J. Obstet. Gynaecol. 119, 810–816 (2012)CrossRef

64.

V.N. Shah, C.S. Shah, J.K. Snell-Bergeon, Type 1 diabetes and risk of fracture: meta-analysis and review of the literature. Diabet. Med. 32, 1134–1142 (2015)CrossRefPubMedPubMedCentral

65.

W. Rathmann, K. Kostev, Fracture risk in patients with newly diagnosed type 2 diabetes: a retrospective database analysis in primary care. J. Diabetes Complicat. 29, 766–770 (2015)CrossRefPubMed

66.

D.L. Kamen, J.D. Alele, Skeletal manifestations of systemic autoimmune diseases. Curr. Opin. Endocrinol. Diabetes Obes. 17, 540–545 (2010)CrossRefPubMed

67.

F. Lombardi, A. Franzese, D. Iafusco, A. del Puente, A. Esposito, F. Prisco, R. Troncone, G. Valerio, Bone involvement in clusters of autoimmune diseases: just a complication? Bone 46, 551–555 (2010)CrossRefPubMed

Titel: Vertebral fractures assessed with dual-energy X-ray absorptiometry in patients with Addison’s disease on glucocorticoid and mineralocorticoid replacement therapy
verfasst von: Valentina Camozzi
Corrado Betterle
Anna Chiara Frigo
Veronica Zaccariotto
Martina Zaninotto
Erica De Caneva
Paola Lucato
Walter Gomiero
Silvia Garelli
Chiara Sabbadin
Monica Salvà
Miriam Dalla Costa
Marco Boscaro
Giovanni Luisetto
Publikationsdatum: 09.08.2017
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 2/2018
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-017-1380-8

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

The relationship among serum lipocalin 2, bone turnover markers, and bone mineral density in outpatient women

Tyrosine kinase inhibitors in iodine-refractory differentiated thyroid cancer: experience in clinical practice

Predictors of improvement in bone mineral density after celiac disease diagnosis

Long lasting prophylaxis of iodine deficiency after a successful information campaign for iodized salt consumption

Clinical profile of juvenile primary hyperparathyroidism: a prospective study